Summit Therapeutics (NASDAQ:SMMT) stock extends gains as lead cancer drug ivonescimab developed with Akeso (AKESF) ...

BeiGene stock has formed an early-stage base with a buy point of 287.88 ahead of its first-quarter results on May 7.

Akeso Pharmaceuticals and Summit Therapeutics have reported that their PD-1/VEGF bispecific antibody has met the primary ...

This obligation is derived from the “considerable effort” needed to demonstrate safety, quality and efficacy of an innovative ...

Designed to provide broad exposure to the Health Care ETFs category of the market, the First Trust NYSE Arca Biotechnology ETF (FBT) is a smart beta exchange traded fund launched on 06/19/2006.

Shares of Summit Therapeutics Inc. (SMMT) surged more than 21% on Wednesday and extended gains in after-hours trading, driven ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, ...